Business Context and Reporting Period
The filing is Synthetic Biologics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2016. The request metadata names Theriva Biologics, Inc.; that does not match the registrant identified in the filing. Synthetic Biologics was a clinical-stage therapeutics company, with Phase 2 programs SYN-010 for IBS-C and SYN-004 to protect the gut microbiome during IV antibiotic treatment. Other programs were preclinical or discovery-stage. The company reported no meaningful product revenue and said it did not expect product revenue in the near term.
Key Financial Metrics
| Metric | Q1 2016 / March 31, 2016 | Comparable period / prior year-end |
|---|---|---|
| Revenue | No revenue reported in the statements of operations | No revenue reported in Q1 2015 |
| Operating expenses | $10.581 million | $8.207 million in Q1 2015 |
| Operating loss | $10.581 million | $8.207 million in Q1 2015 |
| Net loss | $11.078 million; $10.845 million attributable to Synthetic Biologics; $0.12 per share | $12.358 million; $0.17 per share in Q1 2015 |
| Cash and cash equivalents | $15.100 million | $20.818 million at December 31, 2015 |
| Net cash used in operations | $5.674 million | $5.458 million in Q1 2015 |
| Total assets | $22.743 million | $30.845 million at December 31, 2015 |
| Total liabilities | $17.766 million | $15.842 million at December 31, 2015 |
| Current assets / current liabilities | $22.216 million / $17.526 million | $30.337 million / $15.575 million at December 31, 2015 |
| Accumulated deficit | $155.624 million | $144.779 million at December 31, 2015 |
Gross margin and operating margin are not meaningful for this pre-commercial company. The balance sheet reports no borrowings or conventional funded debt; current liabilities include $11.065 million of warrant liabilities. The quarter’s $498,000 warrant fair-value charge was non-cash. Cash declined $5.718 million during the quarter, mainly reflecting operating cash use and $44,000 of capital expenditures.
Material Changes Versus the Prior Comparable Period
- Operating expenses increased 29% to $10.581 million. General and administrative expenses rose 42% to $2.426 million, primarily due to employee costs, legal fees, and stock-based compensation. Research and development expenses rose 26% to $8.155 million, driven by expanded clinical, manufacturing, and research activity.
- Direct program R&D costs shifted: SYN-010 increased to $2.028 million from $229,000, while SYN-004 decreased to $2.480 million from $4.334 million. Indirect R&D costs increased to $3.613 million from $1.336 million.
- Net loss narrowed to $11.078 million from $12.358 million, largely because the prior-year period included a larger non-cash warrant fair-value expense ($4.152 million versus $498,000). Operating loss increased.
- Cash and cash equivalents fell $5.718 million from year-end 2015. The company discontinued its multiple sclerosis/Trimesta program in February 2016 and terminated the related University of California agreements effective May 2, 2016.
Outlook, Risks, and Other Matters
- Management said available cash should fund operations for at least the “foreseeable future,” but did not quantify the runway. It also stated that additional funding will ultimately be required and that no committed financing sources were in place. Future equity financing could dilute shareholders; unavailable or unfavorable financing could force program delays, reductions, or discontinuation.
- Planned milestones at the time of filing included SYN-010 Phase 3 trial initiation in the second half of 2016, following an FDA end-of-Phase 2 meeting; SYN-004 Phase 2b interim analysis in summer 2016 and planned Phase 3 initiation in the first half of 2017. These are forward-looking plans, not assurances.
- The filing described positive topline results from two SYN-010 Phase 2 studies and supportive SYN-004 Phase 2a data. Detailed SYN-010 data and additional SYN-004 Phase 2a data were expected in 2016; the SYN-004 Phase 2b study had enrolled approximately 185 patients toward an expected 370.
- Key risks include clinical and regulatory uncertainty, costs and timing of trials and manufacturing, dependence on future financing and collaborations, and potential dilution. The filing noted that stockholders’ equity was $6.3 million for NYSE MKT listing-threshold discussion, while consolidated total stockholders’ equity was $4.977 million including non-controlling interest; it warned that failure to maintain listing standards could lead to delisting.
- No material legal proceedings, material changes in contractual obligations, or off-balance-sheet arrangements were reported. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important Facts for Investors to Verify
- Confirm the issuer and reporting period: this is a Synthetic Biologics, Inc. filing, not a Theriva Biologics, Inc. filing.
- Verify the cash runway and timing or availability of financing, given $15.1 million of cash, quarterly operating cash use of $5.7 million, and no committed financing.
- Track whether planned clinical milestones occurred and review full trial data, safety results, and FDA feedback for SYN-010 and SYN-004.
- Reconcile the reported $6.3 million of company equity used in the NYSE MKT discussion with $4.977 million of consolidated total stockholders’ equity, and monitor continued listing compliance.
- Assess the potential effects of outstanding options and warrants, including the $11.065 million warrant liability and possible dilution.